Merck & Co's statement indicates dissatisfaction with the revised Medicare drug negotiation program guidance. This could potentially influence investor sentiment, although it's unclear whether this will have a positive or negative impact. The company's stance could be seen as a commitment to addressing constitutional issues, which may be viewed positively. Alternatively, it could be seen as a criticism of regulatory changes, which may be viewed negatively.